RxDoctor Payments Data

Brian Parker, MD

Family Medicine · Cullman, ALNPI 1174977383

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 142 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$422
  • AbbVie$353
  • GSK$304
  • Pfizer$260
  • Astellas Pharma US Inc$110
  • CSL Behring$108
  • plus $601 from 15 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,159 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$226,124
Medicare patients
371
Services billed
9,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$173,820
EliquisApixaban161$120,175
TrulicityDulaglutide108$109,472
MounjaroTirzepatide94$108,460
FarxigaDapagliflozin Propanediol134$101,494
XareltoRivaroxaban81$66,496
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$62,466
JardianceEmpagliflozin47$54,963
JanuviaSitagliptin Phosphate67$44,373
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,273
Spiriva RespimatTiotropium Bromide23$14,852
Breo ElliptaFluticasone/Vilanterol32$13,661
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$10,885
Tresiba Flextouch U-200Insulin Degludec16$9,472
Dexlansoprazole DrDexlansoprazole25$8,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$422$173,820157 claims
PfizerEliquis$260$120,175161 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$304$92,400156 claims
Boehringer IngelheimJardiance, Spiriva Respimat$23$69,81570 claims
Johnson & JohnsonXarelto$76$66,49681 claims
MerckJanuvia, Janumet Xr$25$52,83685 claims
Astellas Pharma US IncMyrbetriq$110$8,11722 claims
AbbVieNamzaric$353$7,32213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →